Bristol-Myers Squibb stock (US1078421011): $15.2B Hengrui Pharma deal announced

Bristol-Myers Squibb on May 12, 2026, unveiled a major collaboration with Hengrui Pharma potentially valued at up to $15.2 billion. The agreement spans 13 early-stage programs in oncology, hematology, and immunology, with Bristol-Myers Squibb paying $600 million upfront plus milestone payments. This partnership aims to accelerate innovative medicine development, according to the company press release as of 05/12/2026.

The stock traded at $55.64 on May 11, 2026, on NYSE after a 0.9% decline despite strong Q1 2026 earnings, per GuruFocus as of 05/11/2026. Q1 revenue hit $11.49 billion, beating estimates of $10.92 billion.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Bristol-Myers Squibb: core business model

Bristol-Myers Squibb develops innovative medicines for serious diseases, focusing on oncology, hematology, immunology, cardiovascular, and neuroscience. The company markets blockbuster drugs like Eliquis for anticoagulation and Opdivo for cancer immunotherapy. Its model relies on R&D investment, strategic partnerships, and global commercialization, with significant US market exposure via NYSE listing.

In Q1 2026, reported on May 11, 2026, the firm posted revenue growth driven by its expanding portfolio amid declining legacy product sales, according to GuruFocus as of 05/11/2026.

Main revenue and product drivers for Bristol-Myers Squibb

Key products include Opdivo (nivolumab), generating substantial oncology revenue, and Eliquis (apixaban), a top cardiovascular drug. Growth areas encompass new immunology assets and hematology treatments. The Hengrui deal bolsters the pipeline with 13 programs, including four cancer candidates from Hengrui and four from Bristol-Myers Squibb, per the press release as of 05/12/2026.

Q1 2026 revenue of $11.49 billion exceeded forecasts, highlighting portfolio strength for US investors tracking biopharma leaders.

Industry trends and competitive position

The biopharma sector faces patent cliffs but benefits from oncology and immunology advances. Bristol-Myers Squibb competes with Pfizer, Merck, and Roche, leveraging a robust pipeline. The Hengrui partnership taps China's innovation hub, securing ex-China rights for key assets, as detailed in NJBIZ as of 05/12/2026.

Why Bristol-Myers Squibb matters for US investors

As a NYSE-listed biopharma giant headquartered in New Jersey, Bristol-Myers Squibb offers US investors exposure to global drug innovation with heavy reliance on the US healthcare market. Its products serve millions, influencing sector ETFs and retirement portfolios.

Conclusion

Bristol-Myers Squibb's $15.2 billion Hengrui deal underscores its pipeline expansion strategy amid solid Q1 results. Despite recent stock pressure, the partnership positions it for growth in high-demand therapeutic areas. Investors monitor execution and milestones ahead.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.